Actively Recruiting
Phase 3 Randomized Study of Axatilimab Plus Corticosteroids Versus Placebo for Initial Treatment of Moderate or Severe Chronic Graft-Versus-Host Disease
Led by Incyte Corporation · Updated on 2026-10-30
240
Participants Needed
131
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating axatilimab combined with corticosteroids compared to placebo plus corticosteroids as the initial treatment for moderate or severe chronic graft-versus-host disease cGVHD. The purpose is to compare the effectiveness of axatilimab in improving event-free survival and other clinical outcomes in patients who have developed cGVHD after allogeneic hematopoietic cell transplantation. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Incyte Corporation. Participants will receive either axatilimab or placebo via intravenous infusion along with corticosteroids given orally or intravenously at protocol-defined doses. The study involves two experimental arms one with axatilimab plus corticosteroids and another with placebo plus corticosteroids. Treatment will be administered according to the study protocol, and participants will be monitored for up to three years to assess efficacy and safety outcomes. During the study, participants will undergo regular assessments including monitoring event-free survival, objective response, overall response, survival rates, and corticosteroid dose reductions. Laboratory tests will measure changes in monocyte counts and bone markers. Safety will be closely tracked through adverse event reporting. The total participation duration can be up to approximately five years, including the treatment period and long-term follow-up for outcomes and safety monitoring.
CONDITIONS
Brief Title
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here